
Sign up to save your podcasts
Or


95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.
Can AI become a universal simulator of biology, helping predict disease, improve drug success rates, and reshape how medicine is developed?
This week on Leading Beyond The Lab, Lawrence Rose sat down with Jean-Philippe Vert, Co-Founder and CEO of Bioptimus, with decades of experience spanning artificial intelligence, computational biology, academia and big tech, including leadership roles at Google, and work influenced by breakthroughs such as DeepMind’s AlphaFold.
In this episode, Jean-Philippe covers:
• Why Bioptimus is focused on understanding patient biology, not simply designing molecules, and why that could change drug development.
• How AI-powered decision systems could improve translational research, clinical trial design, patient recruitment and disease prediction.
• Why Jean-Philippe left Google to build Bioptimus, and why foundation models for biology may represent a major shift in medicine.
• How partnerships across healthcare systems, pharma and research institutions are helping build the data infrastructure behind biological foundation models, with perspectives shaped alongside leaders including Sarah Teichmann (Professor at Cambridge University) and Caroline Uhler (Professor at MIT)
• What makes AI in biology defensible, from proprietary data partnerships and elite interdisciplinary teams, to support from investors including Edward Kliphuis (Sofinnova Partners), Bpifrance, Cathay Investments.
A thoughtful conversation on AI, biology, and the future of medicine. From lessons learned in big tech to what it takes to build enduring platforms in TechBio, this is a considered discussion for anyone interested in where scientific discovery is heading.
Be sure to check out the full episode.
Follow ARTO
LinkedIn: https://www.linkedin.com/company/artotalent
Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng
Instagram: https://www.instagram.com/arto.talent
TikTok: https://www.tiktok.com/@artotalent
Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575
Website: https://arto-talent.com/
Youtube: https://www.youtube.com/@artotalent
Jean-Philippe Vert
CEO at Bioptimus
LinkedIn: https://www.linkedin.com/in/jean-philippe-vert/
Lawrence Rose
Talent Solutions Director at ARTO
LinkedIn: https://www.linkedin.com/in/lawrencerose/
Timestamps
00:00 Introduction and vision for AI as a universal simulator of biology
01:41 Introducing Jean-Philippe Vert and @Bioptimus
02:27 What Bioptimus is doing differently in AI biology
07:46 AI decision systems and improving clinical development
12:52 Early disease detection and predictive healthcare
15:28 Why Jean-Philippe left @Google
19:21 Building and sourcing biological data at scale
22:19 Partnerships and foundation models
28:04 Lessons from big tech
33:23 Defensibility in AI biology
37:09 Building interdisciplinary teams and culture
39:28 AI in healthcare, hype versus infrastructure
41:20 What AI means for doctors
43:10 What may define lasting AI-biology companies
45:05 Challenges of building Bioptimus
48:13 Prioritisation and deciding where to focus
51:33 Mentorship, leadership and building teams
53:02 Communicating vision to boards and investors
55:33 What success looks like in ten years
#LeadingBeyondTheLab #ARTOTalent #TechBio #ArtificialIntelligence #DrugDiscovery #ComputationalBiology #PrecisionMedicine
Hosted on Acast. See acast.com/privacy for more information.
By ARTO Talent95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.
Can AI become a universal simulator of biology, helping predict disease, improve drug success rates, and reshape how medicine is developed?
This week on Leading Beyond The Lab, Lawrence Rose sat down with Jean-Philippe Vert, Co-Founder and CEO of Bioptimus, with decades of experience spanning artificial intelligence, computational biology, academia and big tech, including leadership roles at Google, and work influenced by breakthroughs such as DeepMind’s AlphaFold.
In this episode, Jean-Philippe covers:
• Why Bioptimus is focused on understanding patient biology, not simply designing molecules, and why that could change drug development.
• How AI-powered decision systems could improve translational research, clinical trial design, patient recruitment and disease prediction.
• Why Jean-Philippe left Google to build Bioptimus, and why foundation models for biology may represent a major shift in medicine.
• How partnerships across healthcare systems, pharma and research institutions are helping build the data infrastructure behind biological foundation models, with perspectives shaped alongside leaders including Sarah Teichmann (Professor at Cambridge University) and Caroline Uhler (Professor at MIT)
• What makes AI in biology defensible, from proprietary data partnerships and elite interdisciplinary teams, to support from investors including Edward Kliphuis (Sofinnova Partners), Bpifrance, Cathay Investments.
A thoughtful conversation on AI, biology, and the future of medicine. From lessons learned in big tech to what it takes to build enduring platforms in TechBio, this is a considered discussion for anyone interested in where scientific discovery is heading.
Be sure to check out the full episode.
Follow ARTO
LinkedIn: https://www.linkedin.com/company/artotalent
Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng
Instagram: https://www.instagram.com/arto.talent
TikTok: https://www.tiktok.com/@artotalent
Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575
Website: https://arto-talent.com/
Youtube: https://www.youtube.com/@artotalent
Jean-Philippe Vert
CEO at Bioptimus
LinkedIn: https://www.linkedin.com/in/jean-philippe-vert/
Lawrence Rose
Talent Solutions Director at ARTO
LinkedIn: https://www.linkedin.com/in/lawrencerose/
Timestamps
00:00 Introduction and vision for AI as a universal simulator of biology
01:41 Introducing Jean-Philippe Vert and @Bioptimus
02:27 What Bioptimus is doing differently in AI biology
07:46 AI decision systems and improving clinical development
12:52 Early disease detection and predictive healthcare
15:28 Why Jean-Philippe left @Google
19:21 Building and sourcing biological data at scale
22:19 Partnerships and foundation models
28:04 Lessons from big tech
33:23 Defensibility in AI biology
37:09 Building interdisciplinary teams and culture
39:28 AI in healthcare, hype versus infrastructure
41:20 What AI means for doctors
43:10 What may define lasting AI-biology companies
45:05 Challenges of building Bioptimus
48:13 Prioritisation and deciding where to focus
51:33 Mentorship, leadership and building teams
53:02 Communicating vision to boards and investors
55:33 What success looks like in ten years
#LeadingBeyondTheLab #ARTOTalent #TechBio #ArtificialIntelligence #DrugDiscovery #ComputationalBiology #PrecisionMedicine
Hosted on Acast. See acast.com/privacy for more information.